Last reviewed · How we verify

NCT07088185

Pulmonary Outcomes on Patients With Lung Fibrosis

Active, enrolled NA Last updated 28 July 2025
What this trial tests

NA trial testing Routine medical care in Lung Fibrosis in 60 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 December 2024
Primary endpoint
1 May 2026
1 August 2026

Quick facts

Lead sponsorSouth Valley University
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 December 2024
Primary completion1 May 2026
Estimated completion1 August 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

South Valley University

Who can join

Adults 35 to 55, any sex, with Lung Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The pulmonary fibrosis is lung disease that occurs when lung tissue become damaged and scarred. The objectives of treatment are to improve symptoms and quality of life, and slow disease progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Routine medical care

Trials testing the same drug.

Other recruiting trials for Lung Fibrosis

Currently open trials in the same condition.

Other South Valley University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07088185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing